Collegium Pharmaceutical, Inc.(COLL)Earnings, Financials & Key RatiosCollegium Pharmaceutical, Inc. (COLL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the forward P/E of 4.70 suggests an attractive valuation, the persistent $808.1 million debt load and volatile revenue growth warrant a cautious approach until operating margins stabilize above the 16.5% level observed in 2026Q1.
Collegium Pharmaceutical, Inc. (COLL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Collegium Pharmaceutical, Inc. (COLL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.76vs $1.52+15.8% | $194Mvs $184M+4.9% |
| Q1 2026 | Feb 26, 2026 | $2.04vs $2.14-4.7% | $205Mvs $206M-0.4% |
| Q4 2025 | Nov 6, 2025 | $2.25vs $1.86+21.0% | $209Mvs $206M+1.6% |
| Q3 2025 | Aug 7, 2025 | $1.68vs $1.62+3.7% | $188Mvs $191M-1.7% |
Recent stock market news and headlines for Collegium Pharmaceutical, Inc. (COLL)
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Key metrics vs top competitors for Collegium Pharmaceutical, Inc. (COLL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $37.47 | $1.22B | 21.66 | 23.62% | 8.05% | 23.7% | — | |
| $21.64 | $2.1B | -42.43 | 504.79% | -0.11% | -0.33% | — | |
| $37.01 | $2.14B | 13.66 | 21.51% | 16.2% | 17.19% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $25.59 | $1.01B | 159.94 | 3.63% | 1.27% | 1.31% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — |
Collegium Pharmaceutical, Inc. (COLL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Collegium Pharmaceutical, Inc. (COLL) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 15, 2026·SEC
May 12, 2026·SEC
May 7, 2026·SEC
Get notified when COLL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Collegium Pharmaceutical, Inc. (COLL) stock FAQ — growth, dividends, profitability & financials explained
Collegium Pharmaceutical, Inc. (COLL) reported $796.3M in revenue for fiscal year 2025.
Collegium Pharmaceutical, Inc. (COLL) grew revenue by 23.6% over the past year. This is strong growth.
Yes, Collegium Pharmaceutical, Inc. (COLL) is profitable, generating $74.9M in net income for fiscal year 2025 (8.1% net margin).
Collegium Pharmaceutical, Inc. (COLL) has a return on equity (ROE) of 23.7%. This is excellent, indicating efficient use of shareholder capital.
Collegium Pharmaceutical, Inc. (COLL) generated $329.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
